IT/Healthcare

TargeGen is a vascular biology focused biopharmaceutical company that primarily develops treatments associated with a broad range of human diseases including heart attack, cancer, and eye diseases (macular degeneration, diabetic macular edema, diabetic retinopathy), as well as many other serious medical conditions. TargeGen was acquired by Sanofi-aventis.

• TargeGen was acquired by Sanofi-aventis.